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Abstract 
Neuropeptide Y is implicated in energy homeostasis, and contributes to obesity when hypothalamic 
levels remain chronically elevated. To investigate the specific role of hypothalamic Y2 receptors in this 
process, we used a conditional Y2 knockout model, using the Cre-lox system and adenoviral delivery of 
Cre-recombinase. Hypothalamus-specific Y2-deleted mice showed a significant decrease in body 
weight and a significant increase in food intake that was associated with increased mRNA levels for the 
orexigenic NPY and AgRP, as well as the anorexic proopiomelanocortin (POMC) and cocaine- and 
amphetamine-regulated transcript (CART) in the arcuate nucleus. These hypothalamic changes 
persisted until at least 34 days after Y2 deletion, yet the effect on body weight and food intake subsided 
within this time. Plasma concentrations of pancreatic polypeptide and corticosterone were 3- to 5-fold 
increased in hypothalamus-specific Y2 knockout mice. Germ-line Y2 receptor knockout also produced a 
significant increase in plasma levels of pancreatic polypeptide. However, these mice differed from 
conditional knockout mice in that they showed a sustained reduction in body weight and adiposity 
associated with increased NPY and AgRP but decreased POMC and CART mRNA levels in the arcuate 
nucleus. The transience of the observed effects on food intake and body weight in the hypothalamus-
specific Y2 knockout mice, and the difference of this model from germ-line Y2 knockout mice, underline 
the importance of conditional models of gene deletion, because developmental, secondary, or 
extrahypothalamic mechanisms may mask such effects in germ-line knockouts. 
Abbreviations: NPY, neuropeptide Y; Arc, arcuate nucleus; AgRP, agouti related protein; POMC, 
proopiomelanocortin; CART, cocaine- and amphetamine-regulated transcript; GFP, green fluorescent 
protein; Cre, Cre-recombinase; Neo, neomycin; PP, pancreatic polypeptide; WAT, white adipose tissue.  
 
Neuropeptide Y (NPY) in the hypothalamus is known to be a strong stimulus for food intake (1, 2), and 
induces many neuroendocrine and metabolic changes that favor energy storage. Such changes include 
decreased thermogenesis in brown adipose tissue, hyperinsulinemia, hypercorticosteronemia, and 
insulin hyperresponsiveness in white adipose tissue (3, 4). All of these neuroendocrine and metabolic 
effects of central NPY administration persist even when NPY-induced hyperphagia is prevented by pair-
feeding (3, 4), demonstrating that hyperphagia is not the only mechanism by which central NPY 
increases adiposity. 
 Although numerous other hormones and peptides act within the hypothalamus to regulate 
energy homeostasis, many exert an important component of their effects via actions on the 
hypothalamic NPY-ergic system (5–7), demonstrating the pivotal role of NPY in coordinating energy 
homeostasis. However, it is not clear which of the 5 cloned Y-receptors (Y1, Y2, Y4, Y5, and y6) are 
responsible for these effects (8). 
 There is increasing evidence that Y2 receptors are involved in energy homeostasis. Over 80% 
of NPY-containing neurons in the arcuate nucleus (Arc) coexpress Y2 receptor mRNA (9). This 
presynaptic Y2 receptor has therefore been proposed to regulate the release of NPY (10, 11) and other 
colocalized neurotransmitters involved in energy homeostasis such as agouti related protein (AgRP) 
(12). The existence of such a feedback mechanism has been strengthened by recent reports that show 
that NPY release from rat hypothalamic slices is reduced by the Y2-preferring agonist NPY(13–36), and 
that this effect is blocked by the selective Y2 receptor antagonist (BIIE0246; ref. 13). Further evidence 
for a role of Y2 receptors in energy homeostasis comes from the finding that release of the catabolic 
alpha melanocyte-stimulating hormone (α-MSH), and the expression of its precursor, 
proopiomelanocortin (POMC) mRNA within neurons of the Arc are strongly down-regulated by NPY (14, 
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15). These effects are mimicked by NPY(13–36) but not by the Y1/Y5 agonist [L31,P34]NPY (14, 15). 
 The lack of a full complement of selective pharmacological tools for NPY receptors has made it 
difficult to determine which Y receptors are responsible for the effect of NPY on energy homeostasis. 
Moreover, germ-line knockout mice lacking NPY or the Y1, Y2, or the Y5 receptor surprisingly show 
either no change or increased body weight and/or adiposity (16–20). However, experience has also 
highlighted many pitfalls to a germ-line knockout approach, such as compensatory mechanisms arising 
during development, or secondary effects consequent to germ-line deletion. 
 Therefore, to more directly investigate the role of hypothalamic Y2 receptors in energy 
homeostasis, we have generated a conditional Y2 receptor knockout mouse model. This model, the first 
conditional knockout of a Y receptor, allows specific deletion of hypothalamic Y2 receptors in the adult, 
thus avoiding the potential complications resulting from germ-line knockout. 
 
Materials and Methods 
 
Targeting Vector Construction and Generation of Y2 Receptor Knockout Mice. A 129/SvJ mouse 
genomic bacterial artificial chromosome (BAC) library (Genome Systems, St Louis) was screened under 
low stringency for the Y2 receptor gene by using a human Y2 cDNA probe (21). Positively hybridizing 
clones were isolated and mapped. An 8.5-kb BamHI fragment was subcloned into pBluescript and used 
to generate the targeting construct. A cassette containing the neomycin resistance gene (Neo) flanked 
on either side by a 34-bp-long Cre-recombinase (Cre) recognition (loxP) site orientated in the same 
direction was inserted into a unique Asp718 site downstream of the Y2 gene. A third loxP sequence was 
introduced by cloning two complementary 46-mer oligonucleotides into a NheI site in intron I, 1 kb 
upstream of the Y2 receptor gene initiation codon (Fig. 6, which is published as supporting information 
on the PNAS web site, www.PNAS.org). A 1.2-kb PstI/BamHI fragment 5′ to the Y2 targeting construct 
was used for screening of positively targeted ES cell clones. Mice were genotyped by Southern blot 
analysis (see Results) and PCR using oligo-C (5′-TTAACATCAGCTGGCCTAGC-3′), oligo-D (5′-
GGAAGTCACCAACTAGAATGG-3′) and oligo-E (5′-AGCATCCAGAGAAGTGCAAC-3′), with 35 cycles 
of 94°C for 45 s, 60°C for 1 min, and 72°C for 20 s. 
 
Measurement of Food Intake and Body Weight. Animals were group-housed and fed with standard 
chow. Body weight was monitored at the same time each week from 4 wk of age onwards. Food intake 
was measured over 7 days in individually housed mice at 8 and 12 wk of age. 
 
Tissue Collection and Analysis. At 16–18 wk of age, germ-line Y2 knockout mice were killed by 
cervical dislocation between 1000 and 1400 h, for collection of trunk blood. A subset of Y2+/+ and 
Y2−/− mice received corticosterone in the drinking water (25 mg/liter) for a period of 2 wk before 
sacrifice, during which time body weight, and food and water intake were monitored weekly. Conditional 
knockout mice were killed at 12–14 or 15–17 wk of age (12 or 34 days after Cre-expressing adenovirus 
injection). Mice were killed within 90 s of initial handling to avoid time-dependent increases in 
corticosteronemia. White adipose tissue (WAT) depots (right inguinal, right epididymal or periovarian, 
right retroperitoneal, and mesenteric), pancreas, stomach, liver, right kidney, heart, and right testis were 
collected and weighed. Plasma leptin and insulin levels were measured by RIA kits from Linco Research 
(St. Charles, MO), corticosteronemia was measured with a kit from ICN, and glycemia was determined 
with a glucose oxidase assay kit (Trace Scientific, Melbourne, Australia). Plasma pancreatic polypeptide 
(PP) was radioimmunoassayed by using guinea pig anti-rat PP serum, 2nd Antibody Precipitating 
System (Linco Research) and [125I]hPP (NEN). 
 
Adenovirus Injection. Ten- to 12-wk-old conditional Y2lox/lox and Y2+/+ mice were anesthetized with 
100 mg/kg ketamine and 20 mg/kg xylazine (Parke-Davis-Pfizer; Bayer, Wuppertal, Germany) and 
injected with recombinant Cre- or green fluorescent protein (GFP)-expressing adenovirus (Riken, 
Fukyuka, Japan) using a stereotaxic table (Kopf Instruments, Tujunga, CA). Brain injection coordinates 
relative to bregma were posterior 2.3 mm, lateral ± 0.3 mm, ventral 5.6 mm, corresponding to the Arc 
(22). As additional controls, conditional Y2lox/lox mice were injected with Cre adenovirus into the CA3 
region of the dorsal hippocampus (posterior 2.5 mm, lateral ± 3.0 mm, ventral 3.1 mm; ref. 22). Virus (1 
× 109 plaque-forming units in 1 µl) was injected bilaterally over 10 min by using a 26-gauge guide 
cannula and a 33-gauge injector (Plastics One, Roanoke, VA) connected to a Hamilton Syringe and a 
syringe infusion pump (WPI Instruments, Waltham, MA). Mice were housed individually, and daily food 
and water intake and body weight were measured for the next 12–34 days. 
 
In Situ Hybridization and Receptor Binding. Coronal slices (20 µm) of fresh frozen brains were cut 
and thaw-mounted on charged slides. For in situ hybridization, DNA oligonucleotides complementary to 
mouse NPY (5′-GAGGGTCAGTCCACACAGCCCCATTCGCTTGTTACCTAGCAT-3′);  mouse POMC  
(5′-TGGCTGCTCTCCAGGCACCAGCTCCACACATCTATGGAGG-3′); mouse cocaine- and 
amphetamine-regulated transcript (CART; 5′TCCTTCTCGTGGGACGCATCATCCACGGCAGAGTAG 
ATGTCCAGG-3′); and mouse AgRP (5′-AGCTTGCGGCAGTAGCAAAAGGCATTGAAGAAGCGGCAGT 
AGCAC-3′) mRNAs were labeled with [35S]thio-dATP (Amersham Pharmacia or NEN) using terminal  
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deoxynucleotidyltransferase (Roche, Mannheim, Germany or Amersham Pharmacia). Matching sections 
from the same portion of the hypothalamus of knockout and control mice were assayed together, 
following the method of Young (23) with variations (24, 25). mRNA levels were evaluated by measuring 
silver grain densities over individual neurons from photo-emulsion-dipped sections. 
 Radio ligand binding studies were carried out as described recently (26), by using the Y2/Y5-
selective ligand [125I]PYY(3–36). Autoradiographs were scanned, and relative optical density (ROD) 
values were determined over the stratum oriens CA3. Specific binding was calculated by subtracting 
nonspecific, obtained from sections incubated in 1,000-fold excess of cold ligand, from total binding. 
Background labeling was uniform and never exceeded 5% of total signal. 
 
Statistical Analyses. Differences among groups were assessed by ANOVA (factorial or repeated 
measures), followed by Fisher's post hoc tests, using STATVIEW VERSION 4.5 (Abacus Concepts, 
Berkeley, CA). For all statistical analyses, P < 0.05 was accepted as being statistically significant. 
 
Results 
Generation of Germ-Line and Conditional Y2 Receptor Knockout Mice. A targeting vector for the 
Y2 receptor gene was designed and generated that allowed the production of both germ-line (Y2−/−) 
and conditional (floxed, Y2lox/lox) knockout mice (Fig. 6A). In this construct, no original mouse genomic 
sequence was deleted or rearranged, thus keeping the targeted allele as similar as possible to the 
original gene. 
 Chimeras carrying the Y2 floxed gene were crossed with oozyte-specific Cre-expressing 
C57BL/6 mice (27) to obtain either heterozygotes carrying the floxed gene (conditional, Y2lox/+), or 
heterozygotes carrying the Cre gene and having the floxed gene already deleted (germ-line, Y2+/−). 
Absence of the Y2 gene in homozygote germ-line Y2−/− mice, which also provides verification for the 
functionality of the Cre-lox system, was confirmed by Southern analysis employing a Y2 receptor coding 
sequence-specific DNA fragment and PCR (Fig. 6 B and C). All further mice generated were maintained 
on this mixed C57BL/6–129/SvJ background, and littermates were used as controls. In the case of the 
germ-line Y2 receptor knockouts, animals that no longer carried the Cre-transgene were selected. 
 To confirm that introduction of the loxP sites and the Neo cassette did not alter expression of 
the Y2 receptor gene in our conditional line, we performed radioligand binding experiments on brain 
slices from wild-type Y2+/+, germ-line Y2−/−, and Y2lox/lox animals. As shown in Fig. 6D, whereas 
germ-line Y2−/− mice had negligible [125I]PYY(3–36) binding (relative optical density 0.02), the level of 
binding in uninduced conditional Y2lox/lox mice was comparable to that of wild types (relative optical 
density in CA3: 0.21 vs 0.27), making them suitable controls. 
 
Hypothalamus-Specific Y2 Receptor Gene Deletion. Refinement of the stereotaxic injection 
coordinates was monitored by the appearance of green fluorescence only in cells in the hypothalamus 
of GFP-injected animals. Cre-gene expression and subsequent Y2 receptor gene deletion were 
confirmed at 28 days postadenovirus injection by PCR analysis of DNA isolated from hypothalamic 
blocks. Only DNA isolated from the hypothalamus of Cre-injected Y2lox/lox animals, but not from other 
parts of the brain of the same animals, nor hypothalamic DNA from GFP-injected Y2lox/lox animals, 
gave rise to fragments specific for the Cre gene (Fig. 6C2), and fragments specific for deletion of the Y2 
gene (Fig. 6C3). In the same DNA preparation, fragments specific for the homozygous floxed Y2 gene 
were strongly reduced to ≈10% relative to the controls (Fig. 6C1), further confirming successful deletion 
of the Y2 gene in the majority of the hypothalamic cells. 
 
Effect of Conditional Y2 Receptor Deletion on Body Weight and Food Intake. Hypothalamus-
specific Y2 receptor deletion in HYP CRE-Y2lox/lox mice had significant effects on body weight and 
food intake. These effects were significantly different from the two groups of Cre-injected control mice 
(CA3 CRE-Y2lox/lox, and HYP CRE-Y2+/+), as well as GFP-injected controls (HYP GFP Y2lox/lox), as 
shown in Fig. 1. All groups of mice were of similar initial body weight (27.9 ± 0.6 g in males and 22.3 ± 
0.4 g in females, n = 30–54 mice of each gender), and demonstrated an equivalent drop in body weight 
and food intake on the day after injection (Fig. 1), which is probably due to anesthesia and surgery. At 
7–8 days postinjection, Cre- but not GFP-injected mice underwent a second drop in body weight and 
food intake (Fig. 1). However, compared with control mice, recovery to initial body weight was 
significantly delayed in the hypothalamus-specific Y2 receptor knockouts. Male CA3 CRE-Y2lox/lox and 
HYP CRE-Y2+/+ control mice returned to preinjection body weight within 14 to 22 days postinjection, 
respectively, whereas 100% recovery was delayed until 28 days in the male HYP CRE-Y2lox/lox 
knockouts (Fig. 1A). Female wild-type control mice returned to preinjection body weight within 16 days 
postinjection, but, in female knockouts, recovery to 100% body weight was delayed until 23 days 
postinjection (P < 0.01, n = 6–13 mice per group).   
 Male HYP CRE-Y2lox/lox mice showed a significantly greater food intake than mice in the 
three control groups (Fig. 1B). In female knockout mice, there was also a tendency to greater food 
intake in the postinjection period (5.4 ± 0.2 g/day vs. 5.0 ± 0.2 g/day in Cre-injected wild-type controls 
and 4.1 ± 0.2 g/day in GFP-injected Y2lox/lox controls, n = 6–10 mice per group). 
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Increased Plasma Corticosterone and PP Levels in Hypothalamus-Specific Y2 Knockout Mice. 
Despite the transient reduction in body weight induced by hypothalamus-specific Y2 receptor deletion, 
at 34 days postinjection, these mice were not significantly different from control mice with respect to  
Y2 gene (Fig. 6C3). In the same DNA preparation, fragments
specific for the homozygous floxed Y2 gene were strongly
reduced to !10% relative to the controls (Fig. 6C1), further
confirming successful deletion of the Y2 gene in the majority of
the hypothalamic cells.
Effect of Conditional Y2 Receptor Deletion on Body Weight and Food
Intake. Hypothalamus-specific Y2 receptor deletion in HYP
CRE-Y2lox/lox mice had significant effects on body weight and
food intake. These effects were significantly different from the
two groups of Cre-injected control mice (CA3 CRE-Y2lox/lox,
and HYP CRE-Y2"/"), as well as GFP-injected controls (HYP
GFP Y2lox/lox), as shown in Fig. 1. All groups of mice were of
similar initial body weight (27.9# 0.6 g in males and 22.3# 0.4 g
in females, n $ 30–54 mice of each gender), and demonstrated
an equivalent drop in body weight and food intake on the day
after injection (Fig. 1), which is probably due to anesthesia and
surgery. At 7–8 days postinjection, Cre- but not GFP-injected
mice underwent a second drop in body weight and food intake
(Fig. 1). However, compared with control mice, recovery to
initial body weight was significantly delayed in the hypothala-
mus-specific Y2 receptor knockouts. Male CA3 CRE-Y2lox/lox
and HYP CRE-Y2"/" control mice returned to preinjection
body weight within 14 to 22 days postinjection, respectively,
whereas 100% recovery was delayed until 28 days in the male
HYP CRE-Y2lox/lox knockouts (Fig. 1A). Female wild-type
control mice returned to preinjection body weight within 16 days
postinjection, but, in female knockouts, recovery to 100% body
weight was delayed until 23 days postinjection (P % 0.01, n $
6–13 mice per group).
Male HYP CRE-Y2lox/lox mice showed a significantly greater
food intake than mice in the three control groups (Fig. 1B). In
female knockout mice, there was also a tendency to greater food
intake in the postinjection period (5.4 # 0.2 g!day vs. 5.0 # 0.2
g!day in Cre-injected wild-type controls and 4.1 # 0.2 g!day in
GFP-injected Y2lox/lox controls, n $ 6–10 mice per group).
Increased Plasma Corticosterone and PP Levels in Hypothalamus-
Specific Y2 Knockout Mice.Despite the transient reduction in body
weight induced by hypothalamus-specific Y2 receptor deletion,
at 34 days postinjection, these mice were not significantly
different from control mice with respect to WAT mass, leptine-
mia, insulinemia, and glycemia (data not shown). At 12 days
postinjection, at which time body weight of hypothalamus-
specific knockouts was significantly less than the three groups of
control mice, there was no significant difference between groups
with regard to WATmass, although the insulinemia of knockout
mice tended to be less than control values at this time (58 # 6
vs. 97 # 19, n $ 5–6 male mice per group).
Corticosteronemia of male hypothalamus-specific knockouts
was significantly increased over GFP- or Cre-injected control
mice at 34 days postinjection (Fig. 2A), and this change was
associated with a 4-fold increase in plasma PP levels (Fig. 2B).
In contrast, levels of corticosterone in female mice, which were
already higher than that of male mice under basal conditions,
were not affected by Y2 receptor deletion in conditional knock-
out animals (Fig. 2B). The plasma levels of PP in female mice
were not affected by hypothalamus-specific Y2 deletion
(Fig. 2B).
Effect of Germ-Line Y2 Receptor Deletion on Body Weight and Food
Intake. Male and female germ-line Y2&/& mice had identical
birth-weights as control animals. However, knockout mice had
a significantly lower body weight compared with heterozygous or
wild-type littermates at 4 wk of age, and this difference persisted
throughout the 16 wk of monitoring (Fig. 3A). The daily food
intake of male germ-line Y2&/& mice was significantly less than
that of wild-type controls at 8 wk but not at 12 wk of age (Fig.
3B). In contrast, significantly increased food intake was observed
in female Y2&/& mice at both 8 and 12 wk of age (Fig. 3C).
The reduced body weight of male germ-line Y2 knockout mice
Fig. 1. Conditional Y2 receptor deletion reduces body weight. Body weight
changes (A) and food intake (B) in male Y2lox/lox mice after injection of
Cre-expressing adenovirus into the hypothalamus (HYP CRE-Y2lox/lox, n $ 28)
compared with control Y2lox/lox mice injected into the CA3 region of the
hippocampus (CA3CRE-Y2lox/lox,n$6) or injectedwith controlGFP-expressing
adenovirus in the hypothalamus (HYPGFP-Y2lox!lox,n$6), aswell aswild-type
Y2"/" controls injected in the hypothalamus (HYP CRE-Y2"/", n $ 15). Values
aremeans# SEM. **, P% 0.01HYPCRE-Y2lox/lox vs. HYPCRE-Y2"/"; ##, P% 0.01
vs. GFP-injected controls; @@, P % 0.01 vs. CA3-injected controls.
Fig. 2. Plasma corticosterone and PP levels of male and female hypothala-
mus-specificY2 receptor knockoutmice. (A) Corticosteronemia and (B) plasma
PP levels of Cre adenovirus-injected Y2lox/lox (knockout) mice vs. GFP adeno-
virus-injected Y2lox/lox or Cre adenovirus-injected Y2"/" control mice. Data are
means # SEM of 5–13 mice per group. *, P % 0.05 vs. same-sex control mice:
HYP GFP-Y2lox/lox and HYP CRE-Y2"/" for A, and HYP GFP-Y2lox/lox for B.
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Y2 gene (Fig. 6C3). In the same DNA preparation, fragments
specific for the homozygous floxed Y2 gene were strongly
reduced to !10% relative to the controls (Fig. 6C1), further
confirming successful deletion of the Y2 gene in the majority of
the hypothalamic cells.
Effect of Conditional Y2 Receptor Deletion on Body Weight and Food
Intake. Hypothalamus-specific Y2 receptor deletion in HYP
CRE-Y2lox/lox mice had significant effects on body weight and
food intake. These effects were significantly different from the
two groups of Cre-injected control mice (CA3 CRE-Y2lox/lox,
and HYP CRE-Y2"/"), as well as GFP-injected controls (HYP
GFP Y2lox/lox), as shown in Fig. 1. All groups of mice were of
similar initial body weight (27.9# 0.6 g in males and 22.3# 0.4 g
in females, n $ 30–54 mice of each gender), and demonstrated
an equivalent drop in body weight and food intake on the day
after injection (Fig. 1), which is probably due to anesthesia and
surgery. At 7–8 days postinjection, Cre- but not GFP-injected
mice underwent a second drop in body weight and food intake
(Fig. 1). However, compared with control mice, recovery to
initial body weight was significantly delayed in the hypothala-
mus-specific Y2 receptor knockouts. Male CA3 CRE-Y2lox/lox
and HYP CRE-Y2"/" control mice returned to preinjection
body weight within 14 to 22 days postinjection, respectively,
whereas 100% recovery was delayed until 28 days in the male
HYP CRE-Y2lox/lox knockouts (Fig. 1A). Female wild-type
control mice returned to preinjection body weight within 16 days
postinjection, but, in female knockouts, recovery to 100% body
weight was delayed until 23 days postinjection (P % 0.01, n $
6–13 mice per group).
Male HYP CRE-Y2lox/lox mice showed a significantly greater
food intake than mice in the three control groups (Fig. 1B). In
female knockout mice, there was also a tendency to greater food
intake in the postinjection period (5.4 # 0.2 g!day vs. 5.0 # 0.2
g!day in Cre-injected wild-type controls and 4.1 # 0.2 g!day in
GFP-injected Y2lox/lox controls, n $ 6–10 mice per group).
Increased Plasma Corticosterone and PP Levels in Hypothalamus-
Specific Y2 Knockout Mice.Despite the transient reduction in body
weight induced by hypothalamus-specific Y2 receptor deletion,
at 34 days postinjection, these mice were not significantly
different from control mice with respect to WAT mass, leptine-
mia, insulinemia, and glycemia (data not shown). At 12 days
postinjection, at which time body weight of hypothalamus-
specific knockouts was significantly less than the three groups of
control mice, there was no significant difference between groups
with regard to WATmass, although the insulinemia of knockout
mice tended to be less than control values at this time (58 # 6
vs. 97 # 19, n $ 5–6 male mice per group).
Corticosteronemia of male hypothalamus-specific knockouts
was significantly increased over GFP- or Cre-injected control
mice at 34 days postinjection (Fig. 2A), and this change was
associated with a 4-fold increase in plasma PP levels (Fig. 2B).
In contrast, levels of corticosterone in female mice, which were
already higher than that of male mice under basal conditions,
were not affected by Y2 receptor deletion in conditional knock-
out animals (Fig. 2B). The plasma levels of PP in female mice
were not affected by hypothalamus-specific Y2 deletion
(Fig. 2B).
Effect of Germ-Line Y2 Receptor Deletion on Body Weight and Food
Intake. Male and female germ-line Y2&/& mice had identical
birth-weights as control animals. However, knockout mice had
a significantly lower body weight compared with heterozygous or
wild-type littermates at 4 wk of age, and this difference persisted
throughout the 16 wk of monitoring (Fig. 3A). The daily food
intake of male germ-line Y2&/& mice was significantly less than
that of wild-type controls at 8 wk but not at 12 wk of age (Fig.
3B). In contrast, significantly increased food intake was observed
in female Y2&/& mice at both 8 and 12 wk of age (Fig. 3C).
The reduced body weight of male germ-line Y2 knockout mice
Fig. 1. Conditional Y2 receptor deletion reduces body weight. Body weight
changes (A) and food intake (B) in male Y2lox/lox mice after injection of
Cre-expressing adenovirus into the hypothalamus (HYP CRE-Y2lox/lox, n $ 28)
compared with control Y2lox/lox mice injected into the CA3 region of the
hippocampus (CA3CRE-Y2lox/lox,n$6) or injectedwith controlGFP-expressing
adenovirus in the hypothalamus (HYPGFP-Y2lox!lox,n$6), aswell aswild-type
Y2"/" controls injected in the hypothalamus (HYP CRE-Y2"/", n $ 15). Values
aremeans# SEM. **, P% 0.01HYPCRE-Y2lox/lox vs. HYPCRE-Y2"/"; ##, P% 0.01
vs. GFP-injected controls; @@, P % 0.01 vs. CA3-injected controls.
Fig. 2. Plasma corticosterone and PP levels of male and female hypothala-
mus-sp cificY2 receptor knock utmice. (A) Corticosteronemia and (B) plasma
PP levels of Cre adenovirus-injected Y2lox/lox (knockout) mice vs. GFP adeno-
virus-injected Y2lox/lox or Cre adenovirus-injected Y2"/" control mic . Data are
means # SEM of 5–13 mice per group. *, P % 0.05 vs. same-sex control mice:
HYP GFP-Y2lox/lox and HYP CRE-Y2"/" for A, and HYP GFP-Y2lox/lox for B.
8940 " www.pnas.org!cgi!doi!10.1073!pnas.132043299 Sainsbury et al.
Sainsbury	  et	  al.:	  Important	  role	  of	  hypothalamic	  Y2	  receptors	  in	  body	  weight	  regulation	  revealed	  in	  conditional	  knockout	  mice	  
PNAS,	  99(13):	  8938-­‐8943,	  2002	  
 
WAT mass, leptinemia, insulinemia, and glycemia (data not shown). At 12 days postinjection, at which 
time body weight of hypothalamus-specific knockouts was significantly less than the three groups of 
control mice, there was no significant difference between groups with regard to WAT mass, although the 
insulinemia of knockout mice tended to be less than control values at this time (58 ± 6 vs. 97 ± 19, n = 
5–6 male mice per group). 
 Corticosteronemia of male hypothalamus-specific knockouts was significantly increased over 
GFP- or Cre-injected control mice at 34 days postinjection (Fig. 2A), and this change was associated 
with a 4-fold increase in plasma PP levels (Fig. 2B). In contrast, levels of corticosterone in female mice, 
which were already higher than that of male mice under basal conditions, were not affected by Y2 
receptor deletion in conditional knockout animals (Fig. 2B). The plasma levels of PP in female mice 
were not affected by hypothalamus-specific Y2 deletion (Fig. 2B). 
 
Effect of Germ-Line Y2 Receptor Deletion on Body Weight and Food Intake. Male and female 
germ-line Y2−/− mice had identical birth-weights as control animals. However, knockout mice had a 
significantly lower body weight compared with heterozygous or wild-type littermates at 4 wk of age, and 
this difference persisted throughout the 16 wk of monitoring (Fig. 3A). The daily food intake of male 
germ-line Y2−/− mice was significantly less than that of wild-type controls at 8 wk but not at 12 wk of 
age (Fig. 3B). In contrast, significantly increased food intake was observed in female Y2−/− mice at both 
8 and 12 wk of age (Fig. 3C). 
 The reduced body weight of male germ-line Y2 knockout mice was associated with a 
significant reduction in relative WAT mass (Fig. 4 A and B), but there was no difference between male 
knockouts and controls with respect to leptinemia, insulinemia, nor glycemia (Fig. 4 C–E). Despite 
reduced body weight, WAT mass, leptinemia, insulinemia, and glycemia of female germ-line knockouts 
were no different from wild-type control values (Fig. 4 A–E). There was no difference between germ-line 
Y2 knockout and control mice with respect to mass of any of the organs weighed. 
 
 
Germ-Line Y2 Receptor Knockout Attenuates the Obesity Syndrome Associated with 
Corticosterone Administration. In male wild-type mice, 2-wk corticosterone administration induced an 
obesity syndrome characterized by significant increases in WAT mass, leptinemia, and insulinemia, but 
with no change in body weight or glycemia (Fig. 4 A–E). Food intake of corticosterone-treated male wild-
type mice was not significantly different from untreated wild-type controls (data not shown). In contrast, 
these effects of corticosterone were absent in male germ-line Y2−/− mice (Fig. 4). Corticosterone 
administration significantly reduced body weight in female Y2+/+ and Y2−/− mice (Fig. 4). It also 
significantly increased leptinemia, in the absence of any significant effects on WAT mass, insulinemia, 
or glycemia in female Y2+/+, but not Y2−/−, mice (Fig. 4). There was no significant difference in 
corticosteronemia among control and corticosterone-administered mice (data not shown). 
 
Increased Plasma PP Levels in Germ-Line Y2 Knockout Mice. In contrast to the 
hypercorticosteronemia of male conditional knockout animals, plasma corticosterone levels of germ-line 
was associated with a significant reduction in relative WATmass
(Fig. 4 A and B), but there w no difference betwee ale
knockou s and controls with respect t leptinemia, insulinemia,
nor glycemia (Fig. 4 C–E). D spite reduced body weight, WAT
ma s, leptinemia, insuli emia, and glyce ia of female germ-line
knockouts were no iffer nt from wild-type control values (Fig.
4 A–E). There was no differ nce betwee germ-lin Y2 k ock-
out and control mice with respect to mass of any of the organs
wei hed.
Germ-Line Y2 Receptor Knockout Attenuates the Obesity Syndrome
Ass ciated with Corticoster ne Administration. In male wild-type
mice, 2-wk corticosterone administration induced an obesity
syndrome characterized by significant increases in WAT mass,
leptinemia, and insulinemia, but with no change in body weight
or glycemia (Fig. 4 A–E). Food intake of corticosterone-treated
male wild-type mice was not significantly different from un-
treated wild-type controls (data not shown). In contrast, these
effects of corticosterone were absent in male germ-line Y2!/!
mice (Fig. 4). Corticosterone administration significantly re-
duced body weight in female Y2"/" and Y2!/! mice (Fig. 4). It
also significantly increased leptinemia, in the absence of any
significant effects on WAT mass, insulinemia, or glycemia in
female Y2"/", but not Y2!/!, mice (Fig. 4). There was no
significant difference in corticosteronemia among control and
corticosterone-administered mice (data not shown).
Increased Plasma PP Levels in Germ-Line Y2 Knockout Mice. In
contrast to the hypercorticosteronemia of male conditional
knockout animals, plasma corticosterone levels of germ-line
Y2!/! male and female mice showed a tendency to lower values
compared with control mice (Fig. 5A). However, consistent with
results from the conditional knockout mice, male germ-line
Y2!/! showed a 3-fold increase in plasma PP levels compared
with wild-type controls whereas, in female germ-line Y2!/!
mice, plasma PP levels were not different from control values
(Fig. 5B). As in conditional knockouts and controls, plasma
concentrations of PP were around 10-fold higher in male than in
female mice (Figs. 2B and 5B).
Altered Hypothalamic Neuropeptide Expression in Germ-Line and
Conditional Y2 Receptor Knockout Mice. Selective Y2 receptor
deletion by Cre-adenovirus injection into the hypothalamus of
Y2lox/lox animals caused significant increases in Arc NPY and
AgRP mRNA expression, both at 12 days (by 36–42%) and at
34 days (by 36–50%) postinjection, compared with age-matched
wild-type injected controls (Table 1). Interestingly, POMC
mRNA levels were also increased in Arc neurons of hypothal-
amus-specific Y2 receptor deficient mice at 12 and 34 days
postinjection, compared with wild-type injected animals (Table
1), as was the expression of CART mRNA (by 30%), although
this difference attained statistical significance only at 34 days
postinjection (Table 1). CART expression in the paraventricular
nucleus (PVN) was unchanged (104 # 3.8% and 98 # 3.9% of
control at 12 and 34 days, respectively). In line with increased
food intake and recovery of body weight after the weight loss
induced by Cre-adenovirus injection, wild-type animals investi-
Fig. 3. (A) body weight of germ-line male Y2!/! and female Y2!/! mice
compared with combined wild-type (Y2"/") and heterozygous (Y2#) controls.
Values aremeans# SEM"!!of 20–32mice per group. **, P$ 0.01 vs. same-sex
controls. (B and C) Twenty-four-hour food intake of (B) male and (C) female
germ-line Y2!/!mice vs. wild-type controls, measured at 8 and 12 wk of age.
Values aremeans# SEMof 12–14mice per group. *, P$ 0.05 vs. age-matched
same-sex controls.
Fig. 4. Effect of germ-line Y2 receptor deficiency on body composition and
hormonal and metabolic parameters in male and female mice, under control
conditions and after 2 wk of corticosterone (cort) administration. (A) Body
weight. (B) Combined weight (as a percentage of body weight) of right
inguinal, right epididymal or periovarian, right retroperitoneal, and mesen-
teric WAT. (C) Leptinemia. (D) Insulinemia. (E) Glycemia. Data are means #
SEM of 9–30 mice per group. *, P $ 0.05; and **, P $ 0.01 vs. same-sex Y2"/"
control mice, or between the groups indicated by horizontal bars above
columns.
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Y2−/− male and female mice showed a tendency to lower values compared with control mice (Fig. 5A).  
 
was associated with a significant reduction in relative WATmass
(Fig. 4 A and B), but there was no difference between male
knockouts and controls with respect to leptinemia, insulinemia,
nor glycemia (Fig. 4 C–E). Despite reduced body weight, WAT
mass, leptinemia, insulinemia, and glycemia of female germ-line
knockouts were no different from wild-type control values (Fig.
4 A–E). There was no difference between germ-line Y2 knock-
out and control mice with respect to mass of any of the organs
weighed.
Germ-Line Y2 Receptor Knockout Attenuates the Obesity Syndrome
Associated with Corticosterone Administration. In male wild-type
mice, 2-wk corticosterone administration induced an obesity
syndrome characterized by significant increases in WAT mass,
leptinemia, and insulinemia, but with no change in body weight
or glycemia (Fig. 4 A–E). Food intake of corticosterone-treated
male wild-type mice was not significantly different from un-
treated wild-type controls (data not shown). In contrast, these
effects of corticosterone were absent in male germ-line Y2!/!
mice (Fig. 4). Corticosterone administration significantly re-
duced body weight in female Y2"/" and Y2!/! mice (Fig. 4). It
also significantly increased leptinemia, in the absence of any
significant effects on WAT mass, insulinemia, or glycemia in
female Y2"/", but not Y2!/!, mice (Fig. 4). There was no
significant difference in corticosteronemia among control and
corticosterone-administered mice (data not shown).
Increased Plasma PP Levels in Germ-Line Y2 Knockout Mice. In
contrast to the hypercorticosteronemia of male conditional
knockout animals, plasma corticosterone levels of germ-line
Y2!/! male and female mice showed a tendency to lower values
compared with control mice (Fig. 5A). However, consistent with
results from the conditional knockout mice, male germ-line
Y2!/! showed a 3-fold increase in plasma PP levels compared
with wild-type controls whereas, in female germ-line Y2!/!
mice, plasma PP levels were not different from control values
(Fig. 5B). As in conditional knockouts and controls, plasma
concentrations of PP were around 10-fold higher in male than in
female mice (Figs. 2B and 5B).
Altered Hypothalamic Neuropeptide Expression in Germ-Line and
Conditional Y2 Receptor Knockout Mice. Selective Y2 receptor
deletion by Cre-adenovirus injection into the hypothalamus of
Y2lox/lox animals caused significant increases in Arc NPY and
AgRP mRNA expression, both at 12 days (by 36–42%) and at
34 days (by 36–50%) postinjection, compared with age-matched
wild-type injected controls (Table 1). Interestingly, POMC
mRNA levels were also increased in Arc neurons of hypothal-
amus-specific Y2 receptor deficient mice at 12 and 34 days
postinjection, compared with wild-type injected animals (Table
1), as was the expression of CART mRNA (by 30%), although
this difference attained statistical significance only at 34 days
postinjection (Table 1). CART expression in the paraventricular
nucleus (PVN) was unchanged (104 # 3.8% and 98 # 3.9% of
control at 12 and 34 days, respectively). In line with increased
food intake and recovery of body weight after the weight loss
induced by Cre-adenovirus injection, wild-type animals investi-
Fig. 3. (A) body weight of germ-line male Y2!/! and female Y2!/! mice
compared with combined wild-type (Y2"/") and heterozygous (Y2#) controls.
Values aremeans# SEM"!!of 20–32mice per group. **, P$ 0.01 vs. same-sex
controls. (B and C) Twenty-four-hour food intake of (B) male and (C) female
germ-line Y2!/!mice vs. wild-type controls, measured at 8 and 12 wk of age.
Values aremeans# SEMof 12–14mice per group. *, P$ 0.05 vs. age-matched
same-sex controls.
Fig. 4. Effect of germ-line Y2 receptor deficiency on body composition and
hormonal and metabolic parameters in male and female mice, under control
conditions and after 2 wk of corticosterone (cort) administration. (A) Body
weight. (B) Combined weight (as a percentage of body weight) of right
inguinal, right epididymal or periovarian, right retroperitoneal, and mesen-
teric WAT. (C) Leptinemia. (D) Insulinemia. (E) Glycemia. Data are means #
SEM of 9–30 mice per group. *, P $ 0.05; and **, P $ 0.01 vs. same-sex Y2"/"
control mice, or between the groups indicated by horizontal bars above
columns.
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However, consistent with results from the conditional knockout mice, male germ-line Y2−/− showed a 3-
fold increase in plasma PP levels compared with wild-type controls whereas, in female germ-line Y2−/− 
mice, plasma PP levels were not different from control values (Fig. 5B). As in conditional knockouts and 
controls, plasma concentrations of PP were around 10-fold higher in male than in female mice (Figs. 2B 
and 5B). 
 
Altered Hypothalamic Neuropeptide Expression in Germ-Line and Conditional Y2 Receptor 
Knockout Mice. Selective Y2 receptor deletion by Cre-adenovirus injection into the hypothalamus of 
Y2lox/lox animals caused significant increases in Arc NPY and AgRP mRNA expression, both at 12 
days (by 36–42%) and at 34 days (by 36–50%) postinjection, compared with age-matched wild-type 
injected controls (Table 1). Interestingly, POMC mRNA levels were also increased in Arc neurons of 
hypothalamus-specific Y2 receptor deficient mice at 12 and 34 days postinjection, compared with wild-
type injected animals (Table 1), as was the expression of CART mRNA (by 30%), although this 
difference attained statistical significance only at 34 days postinjection (Table 1). CART expression in 
the paraventricular nucleus (PVN) was unchanged (104 ± 3.8% and 98 ± 3.9% of control at 12 and 34 
days, respectively). In line with increased food intake and recovery of body weight after the weight loss 
induced by Cre-adenovirus injection, wild-type animals investigated at 12 days postinjection exhibited 
significantly lower levels of POMC and CART mRNAs and slightly increased levels of NPY and AgRP 
mRNA in neurons of the Arc relative to wild-type littermates at 34 days postinjection (Table 1). 
 In germ-line Y2 receptor knockout mice, mRNA levels relative to wild-type controls in the Arc 
were 120 ± 4.4% (P = 0.001) for NPY and 140 ± 9.6% (P = 0.003) for AgRP, consistent with the 
changes seen in conditional knockout mice. In contrast to the hypothalamus-specific knockouts, POMC 
and CART expression were significantly reduced in germ-line Y2−/− mice compared with wild-type  
controls (POMC, 83 ± 4.3%, P = 0.007; CART, 73 ± 4.6%, P = 0.01). No significant changes in 
neuropeptide mRNA levels were observed in other hypothalamic (PVN) and subthalamic areas (CART 
98 ± 4.6%; melanin concentrating hormone 100 ± 7.0%; orexin 102 ± 1.8%). Data are mean percentage 
of control ± SEM of 6–7 mice per group. 
 
Discussion 
This study provides in vivo evidence for the involvement of hypothalamic Y2 receptors in energy 
homeostasis, because specific and permanent deletion of these receptors by central injection of Cre-
expressing adenovirus in Y2lox/lox adult mice resulted in reduced body weight in association with 
increased food intake. Moreover, adaptation to these effects of hypothalamic Y2 receptor deletion 
gated at 12 days postinjection exhibited significantly lower levels
of POMC and CART mRNAs and slightly increased levels of
NPY and AgRP mRNA in neurons of the Arc relative to
wild-type littermates at 34 days postinjection (Table 1).
In germ-line Y2 receptor knockout mice, mRNA levels relative
to wild-type controls in the Arc were 120 ! 4.4% (P " 0.001) for
NPY and 140 ! 9.6% (P " 0.003) for AgRP, consistent with the
changes seen in conditional knockout mice. In contrast to the
hypothalamus-specific knockouts, POMC and CART expression
were significantly reduced in germ-line Y2#/#mice compared with
wild-type controls (POMC, 83 ! 4.3%, P " 0.007; CART, 73 !
4.6%, P " 0.01). No significant changes in neuropeptide mRNA
levels were observed in other hypothalamic (PVN) and subthalamic
areas (CART 98 ! 4.6%; melanin concentrating hormone 100 !
7.0%; orexin 102! 1.8%). Data are mean percentage of control!
SEM of 6–7 mice per group.
Discussion
This study provides in vivo evidence for the involvement of
hypothalamic Y2 receptors in energy homeostasis, because
specific and p rmanent deletion of these receptors by central
injection of Cre- xpressing ad novirus n Y2lox/lox adul mice
resulted in reduc d body weight in ssociation with increas d
food intake. Moreover, adaptation to these effects of hypotha-
lamic Y2 receptor deletion occurred within 23–28 days.
We also demonstrate that endogenous Y2 receptors are
involved in tonic inhibition of NPY and AgRP expression in
neurons of the Arc, because conditional Y2 receptor deletion
significantly increased the mRNA levels of these colocalized (12)
peptides. This change may have contributed to the increased
food intake observed in the hypothalamus-specific Y2 receptor
knockout mice. The transiently decreased body weight of con-
ditional Y2 receptor knockout mice was associated with in-
creased mRNA expression of the anorexic POMC and CART,
in keeping with a causal relationship. These data show a role
(direct or indirect) of endogenous Y2 receptors in regulating
POMC and CART expression in vivo.
Conditional Y2 receptor knockout resulted in a robust in-
crease in the plasma concentrations of PP specifically in male but
not female mice, suggesting hypothalamic regulation of the
plasma levels of this hormone. PP is released from F-cells in the
islets of Langerhans in response to stimuli such as ingestion of
food, hypoglycemia, or neuroglucopenia, predominantly via a
vagal, muscarinic mechanism (28, 29). PP may contribute to the
counterregulatory response to hypoglycemia by stimulating ad-
renal glucocorticoid secretion, as seen in vitro and in vivo (30,
31). The increased plasma PP levels of male hypothalamus-
specific knockout mice may have contributed to the associated
increase in corticosteronemia in these mice.
This study has also revealed effects of Cre adenovirus injection
in control mice on body weight and food intake. These effects
were probably due to Cre expression per se (32) and were not
observed after GFP adenovirus injection. Toxicity of Cre at high
but not low expression levels has been reported in vitro (33) and
is probably due to interaction of the enzyme with pseudo-loxP
sites. This finding exemplifies the importance of using adeno-
Cre-injected control mice to determine specific effects of adeno-
Cre-induced gene deletion.
Our direct comparison of the phenotype of conditional vs.
germ-line Y2 receptor knockout mice has revealed differences
that are likely to be due to either compensatory mechanisms
arising during development, secondary effects consequent to
germ-line deletion, or effects of deleting Y2 in peripheral as well
as hypothalamic tissue. Notably, in contrast to male conditional
knockouts, male germ-line Y2 knockout mice displayed signif-
icantly reduced body weight, food intake, and WAT mass. These
effects may be the result of long-term elevations in plasma PP
levels seen specifically in male Y2#/# mice. This result is
supported by findings that PP-overexpressing transgenic mice
exhibit reductions in body weight, food intake, and fat mass (34).
Furthermore, human obesity syndromes, as well as genetically
obese ob!ob mice, demonstrate reduced plasma levels of PP,
whereas aspects of these obese phenotypes, including hyperpha-
gia, are attenuated by exogenous PP administration (35–37).
A further difference between conditional and germ-line Y2
knockout was the effect on corticosteronemia. Unlike condi-
tional knockout of Y2, germ-line knockout did not increase the
plasma concentrations of this hormone. This difference may be
related to the fact that prolonged activation of the hypothalamo-
pituitary-adrenal axis can eventually lead to down-regulation of
this axis at the level of the hypothalamus (4). Of note is the
observation that Y2 receptor deficiency also reduced the re-
sponsiveness of mice to exogenous corticosterone administra-
tion. In wild-type mice, corticosterone administration resulted in
an obesity syndrome, which has been observed by other inves-
tigations of rats (6) and mice (38). This finding may be related
to the fact that glucocorticoids are known to increase NPY
mRNA and!or peptide levels and Y receptor expression in the
Fig. 5. Plasma corticosterone and PP levels of male and female germ-line Y2
receptor knockout mice. (A) Corticosteronemia and (B) plasma PP levels of
germ-line Y2#/#mice vs. Y2$/#mice or Y2$/$ control mice. Data are means!
SEM of 9–19 mice per group. *, P % 0.05 vs. same-sex Y2$/$ control mice.
Table 1. Expression levels of neuropeptide mRNAs in neur ns f the Arc at 12 and 34 days after Cre-expressing
ade ovi us inj ction
mRNA Wild type, 12 days Y2lox!lox, 12 days Wild type, 34 days Y2lox!lox, 34 days
NPY 18.3 ! 1.34 (4) 24.8 ! 2.25 (5)* 16.0 ! 0.43 (5) 24.0 ! 2.54 (4)**
AgRP 16.6 ! 1.42 (4) 23.5 ! 1.67 (5)** 14.9 ! 1.00 (5) 19.0 ! 0.83 (4)*†
POMC 23.6 ! 1.10 (4) 27.0 ! 1.41 (5)* 33.3 ! 0.45 (5)‡ 36.5 ! 0.74 (4)*‡
CART 12.9 ! 1.09 (4) 16.8 ! 0.41 (5) 30.5 ! 2.53 (5)‡ 39.5 ! 3.27 (4)**‡
Data rep esent mean labeling intensity of neurons given as per entage coverage of neuronal surface by silvergrains ! SEM of the
number of mice shown in parentheses. *, P % 0.05; **, P % 0.01 vs. respective wild-type control group. †, P % 0.05 vs. respective group
at 12 days. ‡, P % 0.01 vs. respective group at 12 days.
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gated at 12 days postinjection exhibited significantly lower levels
of POMC and CART mRNAs and slightly increased levels of
NPY and AgRP mRNA in neurons of the Arc relative to
wild-type littermates at 34 days postinjection (Table 1).
In germ-line Y2 receptor knockout mice, mRNA levels relative
to wild-type controls in the Arc were 120 ! 4.4% (P " 0.001) for
NPY and 140 ! 9.6% (P " 0.003) for AgRP, consistent with the
changes seen in conditional knockout mice. In contrast to the
hypothalamus-specific knockouts, POMC and CART expression
were significantly reduced in germ-line Y2#/#mice compared with
wild-type controls (POMC, 83 ! 4.3%, P " 0.007; CART, 73 !
4.6%, P " 0.01). No significant changes in neuropeptide mRNA
levels were observed in other hypothalamic (PVN) and subthalamic
areas (CART 98 ! 4.6%; melanin concentrating hormone 100 !
7.0%; orexin 102! 1.8%). Data are mean percentage of control!
SEM of 6–7 mice per group.
Discussion
This study provides in vivo evidence for the involvement of
hypothalamic Y2 receptors in energy homeostasis, because
specific and permanent deletion of these receptors by central
injection of Cre-expressing adenovirus in Y2lox/lox adult mice
resulted in reduced body weight in association with increased
food intake. Moreover, adaptation to these effects of hypotha-
lamic Y2 receptor deletion occurred within 23–28 days.
We also demonstrate that endogenous Y2 receptors are
involved in tonic inhibition of NPY and AgRP expression in
neurons of the Arc, because conditional Y2 receptor deletion
significantly increased the mRNA levels of these colocalized (12)
peptides. This change may have contributed t the increased
food intake observed in the hypothalamus-specific Y2 receptor
knockout mice. The transiently decreased body weight of con-
ditional Y2 receptor knockout mice was associated with in-
creased mRNA expression of the anorexic POMC and CART,
in keeping with a causal relationship. These data show a role
(direct or indirect) of endogenous Y2 receptors in regulating
POMC and CART expression in vivo.
Conditional Y2 receptor knockout resulted in a robust in-
crease in the plasma concentrations of PP specifically in male but
not female mice, suggesting hypothalamic regulation of the
plasma levels of this hormone. PP is released from F-cells in the
islets of Langerhans in response to stimuli such as ingestion of
food, hypoglycemia, or neuroglucopenia, predominantly via a
vagal, muscarinic mechanism (28, 29). PP may contribute to the
counterregulatory response to hypoglycemia by stimulating ad-
renal glucocorticoid secretion, as seen in vitro and in vivo (30,
31). The increased plasma PP levels of male hypothalamus-
specific knockout mice may have contributed to the associated
increase in corticosteronemia in these mice.
This study has also revealed effects of Cre adenovirus injection
in control mice on body weight and food intake. These effects
were probably due to Cre expression per se (32) and were not
observed after GFP adenovirus injection. Toxicity of Cre at high
but not low expression levels has been reported in vitro (33) and
is probably due to interaction of the enzyme with pseudo-loxP
sites. This finding exemplifies the importance of using adeno-
Cre-injected control mice to determine specific effects of adeno-
Cre-induced gene deletion.
Our direct comparison of the phenotype of conditional vs.
germ-line Y2 receptor knockout mice has revealed differences
that are likely to be due to either compensatory mechanisms
arising during development, secondary effects consequent to
germ-line deletion, or effects of deleting Y2 in peripheral as well
as hypothalamic tissue. Notably, in contrast to male conditional
knockouts, male germ-line Y2 knockout mice displayed signif-
icantly reduced body weight, food intake, and WAT mass. These
effects may be the result of long-term elevations in plasma PP
levels seen specifically in male Y2#/# mice. This result is
supported by findings that PP-overexpressing transgenic mice
exhibit reductions in body weight, food intake, and fat mass (34).
Furthermore, human obesity syndromes, as well as genetically
obese ob!ob mice, demonstrate reduced plasma l vels of PP,
whereas aspects of these obese phenotypes, including hyp rpha-
gia, are attenuated by exogenous PP administration (35–37).
A further difference between conditional and germ-line Y2
knockout was the effect on corticosteronemia. Unlike condi-
tional knockout of Y2, germ-line knockout did not increase the
plasma concentrations of this hormone. This difference may be
related to the fact that prolonged activation of the hypothalamo-
pituitary-adrenal axis can eventually lead to down-regulation of
this axis at the level of the hypothalamus (4). Of note is the
observation that Y2 receptor deficiency also reduced the re-
sponsiveness of mice to exogenous corticosterone administra-
tion. In wild-type mice, corticosterone administration resulted in
an obesity syndrome, which h s been observed by oth r i ves-
tigations of rats (6) and mice (38). This finding m y be related
to the fact that glucocorticoids are known to increase NPY
mRNA and!or peptide levels and Y receptor expression in the
Fig. 5. Plasma corticosterone and PP levels of male and female germ-line Y2
receptor knockout mice. (A) Corticosteronemia and (B) plasma PP levels of
germ-line Y2#/#mice vs. Y2$/#mice or Y2$/$ control mice. Data are means!
SEM of 9–19 mice per group. *, P % 0.05 vs. same-sex Y2$/$ control mice.
Table 1. Expression levels of neuropeptide mRNAs in neurons of the Arc at 12 and 34 days after Cre-expressing
adenovirus injection
mRNA Wild type, 12 days Y2lox!lox, 12 days Wild type, 34 days Y2lox!lox, 34 days
NPY 18.3 ! 1.34 (4) 24.8 ! 2.25 (5)* 16.0 ! 0.43 (5) 24.0 ! 2.54 (4)**
AgRP 16.6 ! 1.42 (4) 23.5 ! 1.67 (5)** 14.9 ! 1.00 (5) 19.0 ! 0.83 (4)*†
POMC 23.6 ! 1.10 (4) 27.0 ! 1.41 (5)* 33.3 ! 0.45 (5)‡ 36.5 ! 0.74 (4)*‡
CART 12.9 ! 1.09 (4) 16.8 ! 0.41 (5) 30.5 ! 2.53 (5)‡ 39.5 ! 3.27 (4)**‡
Data represent mean labeling intensity of neurons given as percentage coverage of neuronal surface by silvergrains ! SEM of the
number of mice shown in parentheses. *, P % 0.05; **, P % 0.01 vs. respective wild-type control group. †, P % 0.05 vs. respective group
at 12 days. ‡, P % 0.01 vs. respective group at 12 days.
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occurred within 23–28 days. 
 We also demonstrate that endogenous Y2 receptors are involved in tonic inhibition of NPY and 
AgRP expression in neurons of the Arc, because conditional Y2 receptor deletion significantly increased 
the mRNA levels of these colocalized (12) peptides. This change may have contributed to the increased 
food intake observed in the hypothalamus-specific Y2 receptor knockout mice. The transiently 
decreased body weight of conditional Y2 receptor knockout mice was associated with increased mRNA 
expression of the anorexic POMC and CART, in keeping with a causal relationship. These data show a 
role (direct or indirect) of endogenous Y2 receptors in regulating POMC and CART expression in vivo. 
 Conditional Y2 receptor knockout resulted in a robust increase in the plasma concentrations of 
PP specifically in male but not female mice, suggesting hypothalamic regulation of the plasma levels of 
this hormone. PP is released from F-cells in the islets of Langerhans in response to stimuli such as 
ingestion of food, hypoglycemia, or neuroglucopenia, predominantly via a vagal, muscarinic mechanism 
(28, 29). PP may contribute to the counterregulatory response to hypoglycemia by stimulating adrenal 
glucocorticoid secretion, as seen in vitro and in vivo (30, 31). The increased plasma PP levels of male 
hypothalamus-specific knockout mice may have contributed to the associated increase in 
corticosteronemia in these mice. 
 This study has also revealed effects of Cre adenovirus injection in control mice on body weight 
and food intake. These effects were probably due to Cre expression per se (32) and were not observed 
after GFP adenovirus injection. Toxicity of Cre at high but not low expression levels has been reported 
in vitro (33) and is probably due to interaction of the enzyme with pseudo-loxP sites. This finding 
exemplifies the importance of using adeno-Cre-injected control mice to determine specific effects of 
adeno-Cre-induced gene deletion. 
 Our direct comparison of the phenotype of conditional vs. germ-line Y2 receptor knockout mice 
has revealed differences that are likely to be due to either compensatory mechanisms arising during 
development, secondary effects consequent to germ-line deletion, or effects of deleting Y2 in peripheral 
as well as hypothalamic tissue. Notably, in contrast to male conditional knockouts, male germ-line Y2 
knockout mice displayed significantly reduced body weight, food intake, and WAT mass. These effects 
may be the result of long-term elevations in plasma PP levels seen specifically in male Y2−/− mice. This 
result is supported by findings that PP-overexpressing transgenic mice exhibit reductions in body 
weight, food intake, and fat mass (34). Furthermore, human obesity syndromes, as well as genetically 
obese ob/ob mice, demonstrate reduced plasma levels of PP, whereas aspects of these obese 
phenotypes, including hyperphagia, are attenuated by exogenous PP administration (35–37). 
   A further difference between conditional and germ-line Y2 knockout was the effect on 
corticosteronemia. Unlike conditional knockout of Y2, germ-line knockout did not increase the plasma 
concentrations of this hormone. This difference may be related to the fact that prolonged activation of 
the hypothalamo-pituitary-adrenal axis can eventually lead to down-regulation of this axis at the level of 
the hypothalamus (4). Of note is the observation that Y2 receptor deficiency also reduced the 
responsiveness of mice to exogenous corticosterone administration. In wild-type mice, corticosterone 
administration resulted in an obesity syndrome, which has been observed by other investigations of rats 
(6) and mice (38). This finding may be related to the fact that glucocorticoids are known to increase NPY 
mRNA and/or peptide levels and Y receptor expression in the hypothalamus in vivo (6, 39) and in vitro 
(39). The present study demonstrates that glucocorticoid excess mediates at least part of its effects 
through Y2 receptors. This finding, in conjunction with altered corticosteronemia in hypothalamus-
specific Y2 receptor knockout mice, suggests involvement of Y2 receptors in regulation of hypothalamo-
pituitary-adrenal axis output and responses. 
 Further differences between conditional and germ-line Y2 knockout mice were observed at the 
level of hypothalamic peptide expression. In contrast to conditional knockouts, germ-line knockout mice 
showed increased NPY and AgRP but decreased POMC and CART mRNA levels in the Arc, despite the 
reduced body weight of the latter model. This hypothalamic profile, which has been observed in obese 
rodent models (40, 41), may be a secondary adaptation to germ-line Y2 receptor knockout that reduces 
further weight loss, and underscores the importance of time-controlled conditional knockout models for 
the analysis of energy homeostasis. 
 This study has revealed sex differences in several parameters of energy homeostasis, as well 
as in responses to conditional or germ-line Y2 receptor knockout. For example, plasma PP 
concentrations were higher in male than in female mice, and Y2 deletion led to significant increases in 
the plasma levels of this hormone only in male animals. The reason for these gender differences is not 
clear from the current study. However, it is likely that the differential effect of Y2 deletion on plasma PP 
levels in male and female mice may account for some of the other gender differences found in Y2 
knockouts, such as the differential effect of conditional Y2 deletion on corticosteronemia in male and 
female mice, and the sex differences in food intake and adiposity in germ-line Y2 knockouts. A further 
gender difference observed in this study was that basal corticosteronemia was higher in female than in 
male wild-type mice, and females were less responsive to the effect of exogenous corticosterone in 
inducing an obesity syndrome. This finding extends previous observations of sexual dimorphism in 
function of the hypothalamo-pituitary-adrenal axis in rodents (42). 
 There are differences between the reduced body weight of our germ-line Y2−/− animals and 
the recently published results from another germ-line Y2 receptor knockout model (17), in which female 
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knockouts exhibited increased food intake, body weight, and adiposity. The phenotypic differences of 
male mice were not discussed in detail in that report. However, the genetic backgrounds of the two 
knockout models differ. Our mice are on a mixed C57BL/6 × 129/SvJ background, whereas the other 
model is on a mixed 129/SvJ × BALB/c background, which makes direct comparisons difficult. Perhaps 
more importantly, the design of our construct leads to complete removal of the Y2 receptor gene, 
including the initiation codon as well as the Neo selection gene. In the previous study, the targeting 
construct allowed for translation of parts of the amino-terminal end of the Y2 receptor protein (which 
could interfere with other functions of the cell) and furthermore, it still carried the Neo gene with its 
strong promoter, which could alter the function of nearby genes. 
 In summary, we have established a mouse model that allows the investigation of a variety of 
Y2 receptor functions by selectively deleting the gene in any given tissue, both centrally as well as 
peripherally. This result is demonstrated by our hypothalamus-specific Y2 receptor knockout, which 
provides more direct insight into the role of hypothalamic Y2 receptors in energy homeostasis than 
germ-line knockouts. Investigation of these mice showed that hypothalamic Y2 receptors regulate 
expression of NPY, AgRP, POMC, and CART, and that these changes are associated with functional 
changes in food intake and body weight. Although deletion of the Y2 receptor in the hypothalamus of the 
conditional knockouts is permanent, and the effect of gene deletion on hypothalamic expression of 
peptides persists for at least 34 days, the effects on body weight and food intake are transient, 
consistent with adaptation to maintain homeostasis in these vital processes. 
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